ValuEngine upgraded shares of Novan (NASDAQ:NOVN) from a strong sell rating to a sell rating in a report released on Friday morning.
A number of other brokerages have also recently issued reports on NOVN. Zacks Investment Research upgraded shares of Novan from a sell rating to a hold rating in a report on Wednesday, October 4th. Wedbush restated a neutral rating and set a $6.00 price target on shares of Novan in a report on Monday, September 25th. Finally, Piper Jaffray Companies restated a buy rating on shares of Novan in a report on Thursday, August 3rd.
Shares of Novan (NOVN) traded down $0.15 during midday trading on Friday, hitting $4.86. 39,200 shares of the stock were exchanged, compared to its average volume of 221,519. Novan has a 52-week low of $3.52 and a 52-week high of $30.90.
WARNING: “Novan (NOVN) Upgraded at ValuEngine” was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.com-unik.info/2017/12/04/novan-novn-upgraded-at-valuengine.html.
Novan Company Profile
Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Novan Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novan Inc. and related companies.